Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental labeling approval for canagliflozin; this is a regulatory action, not a clinical study, and does not report efficacy or safety trial outcomes.